The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

About one third of lung transplant recipients have a genetic variant that makes them more likely to develop chronic lung ...

Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...

From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...

Medical University of South Carolina scientists have uncovered a link between the innate immune system and cognitive problems ...

A rare but severe stem cell transplant complication that often becomes fatal now has its first FDA-approved treatment, a therapy developed by biotechnology company Omeros. The Christmas Eve regulatory ...

In the heavy-duty truck segment, Fan said methanol-hydrogen trucks show several advantages over battery electric models: ...

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

SportSG will calibrate its support for these sports based on their "specific needs, governance standards and contributions to ...

A new study shows human immune systems differ across populations, raising new questions for medicine and global drug research ...